Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California. Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin in Phase 3 trial program for the treatment of obesity; APD791, an anti-thrombotic drug candidate, which has completed Phase 1a and Phase 1b clinical trials; and APD125 that is in Phase 2b clinical trial for the treatment of insomnia. The company's clinical development programs also include APD597, an oral GPR119 agonist that is in Phase 1 clinical trial for the treatment of type 2 diabetes; APD916 drug candidate, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. Its drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including constitutively activated receptor technology and melanophore technology.

MedImmune works to boost the immune systems of babies and grown-ups. Its flagship biotech product, Synagis, prevents respiratory syncytial virus (RSV), a major cause of pneumonia and other respiratory disease in infants and children. Also on the market are FluMist, its nasal spray flu vaccine, and Ethyol, which treats side effects of chemotherapy and radiation. The company is working on dozens of investigational therapies -- including monoclonal antibodies, vaccines, and small molecule drugs -- in the areas of infectious diseases, cancer, and inflammatory conditions. MedImmune is a subsidiary of UK-based pharmaceutical giant AstraZeneca.

Myriad Genetics, Inc. company was founded in 1991 and is headquartered in Salt Lake City, Utah. Myriad Genetics, Inc., a healthcare company, focuses on the development and marketing of novel molecular diagnostic products. It commercializes predictive medicine, personalized medicine, and prognostic medicine products. The company markets BRACAnalys for assessing a woman's risk for breast and ovarian cancer; COLARIS molecular for assessing a person's risk of developing colorectal cancer or uterine cancer; COLARIS AP, a molecular diagnostic product for colon cancer that detects mutations in the APC and MYH genes; and MELARIS, which assesses a persons risk of developing melanoma. It also offers OnDose, a personalized medicine product to measure a patient's exposure to 5-FU chemotherapy; PREZEON that assesses loss of PTEN function in cancer patients; and TheraGuide 5-FU assesses a person's risk of developing a toxic reaction to 5-FU-based chemotherapy.

Nile Therapeutics, Inc. company was founded in 2005 and is based in San Mateo, California. Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for the treatment of cardiovascular disease and other areas of unmet medical needs. The company focuses on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. Nile is also developing CU-NP, a novel, rationally designed natriuretic peptide.

Chai-Na-Ta Corp., together with its subsidiaries, engages in growing, processing, and marketing North American ginseng. The company offers ginseng in various forms, such as capsule, slice, tablet, tea, powder, extract, and whole root form, as well as an additive to various consumer products. Ginseng Farming Asian or Korean ginseng (Panax ginseng C.A. Meyer), is a herb indigenous to the mountainous forests of eastern Asia. The North American ginseng (Panax quinquefolius) is a woodland plant native to North America. As of December 31, 2008, the company had under lease 473 acres and owned 270 acres of farmland of which 392 are under ginseng cultivation in Ontario. Sales and Marketing The company sells its products primarily in Hong Kong, China, Canada, and the United States. Subsidiaries The company’s wholly-owned subsidiary, Chai-Na-Ta Farms Ltd. (CNT Farms), carries out the planting, growing, and harvesting of the company’s ginseng crops. CNT Farms also handles the storage of root inventory and manages the distribution of inventory directly to local customers or to customers in the Far East through CNT Trading (Hong Kong) Limited. CNT Farms also carries out crop research. The company through its wholly owned subsidiary, CNT Trading (Hong Kong) Limited (CNT HK), carries out direct marketing, sales, and distribution functions for North American ginseng in Hong Kong for distribution through Asia. CNT HK sells ginseng roots directly to brokers, distributors, and certain customers in the Far East, primarily China. The company through its wholly-owned subsidiary, CNT Nutraceuticals Ltd. (CNTN), operates a showroom in Richmond, British Columbia and carries out direct marketing and sales of graded roots and ginseng-based value-added products to customers in Canada. History The company was founded in 1981. It was formerly known as Chai-Na-Ta Ginseng Products Limited and changed its name to Chai-Na-Ta Corp. in 1994.

Hikma Pharmaceuticals was founded in 1978 by chairman Samih Darwazah. Hikma Pharmaceuticals Plc is a speciality pharmaceutical company with operations in Europe and the United States and a focus in the Middle East and North Africa (MENA) region. The Company develops, manufactures and markets branded and unbranded generic, as well as in-licensed products in both oral and injectable dosage forms. Its operations are conducted through three segments: Branded Pharmaceuticals, Generic Pharmaceuticals and Injectable Pharmaceuticals. Hikma Pharmaceuticals Plc’s Branded Pharmaceuticals segment develops, manufactures and markets 241 solid, semi-solid and liquid branded pharmaceutical products in 460 dosage strengths and forms, including 33 products under-license from the originator. Injectable Pharmaceuticals segment develops, manufactures and markets 81 injectable products in 202 dosage strengths. Generic Pharmaceuticals develops, manufactures and markets 47 non-branded generic pharmaceutical products in 105 dosage strengths and forms.

Since its establishment in 1982, Orgenics' objective has been to develop accurate and safe diagnostic products for serious and life-threatening conditions and diseases. Orgenics contributes to the increased awareness and early detection of HIV, infectious diseases, pregnancy and fertility, respiratory diseases, cancer and cardiology through clinical and point-of-care diagnostics. Orgenics delivers products and solutions to partners and customers in over 150 countries around the globe.Orgenics unique and patented ImmunoComb® technology is quick and easy to use, providing high sensitivity and specificity. Instrument free Orgenics' ImmunoComb® kits are ideal for decentralized clinical laboratories, field hospitals and remote rural areas. Orgenics' ImmunoLISA™ system is based on classic ELISA assay principle and is suitable for any laboratory setting.

Chimerix, Inc. company was founded in 2002 and is headquartered in Durham, North Carolina. Chimerix has developed technology to make molecules with therapeutic potential into oral drugs. Its lipid conjugate technology can modify drug compounds to mimic a particular lipid metabolite that is absorbed by the small intestine, thus protecting the compounds from being broken down in the stomach. Chimerix is using its technology to develop lead drug candidate CMX001 to fight smallpox infections or bad reactions to smallpox vaccinations. The development-stage firm is also targeting drug-resistant HIV and hepatitis.

Nabi Biopharmaceuticals company was founded in 1967 and is headquartered in Rockville, Maryland. Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company is developing NicVAX, a proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland.

Ferring Pharmaceuticals is owned by Swiss drugmaker Ferring Group, which was founded in 1951 and expanded into the US in the early 1980s. Ferring Pharmaceuticals knows that birthing babies is hard work. The company develops and markets a variety of fertility products, including hormone treatments Bravelle, Menopur, Novarel, and Repronex. The company also develops and manufactures products to diagnose and treat ailments in the areas of urology, endocrinology, osteoarthritis, and gastroenterology, including Euflexxa for osteoarthritis of the knee, Prosed for lower urinary tract infections, and Acthrel, a diagnostic agent for Cushing's syndrome.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.